Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C
Status:
Completed
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the safety and efficacy of KW-136, an investigational
anti-hepatitis C virus (HCV) drug, combined with sofosbuvir for treatment of Chinese adults
chronically infected with HCV. Thirty (30) non-cirrhotic subjects were medicated with KW-136
30 mg daily, 60 non-cirrhotic subjects with KW-136 60 mg daily, and 30 cirrhotic subjects
with KW-136 60 mg daily; all the 120 subjects received sofosbuvir 400 mg daily. The treatment
course lasted 12 successive weeks and thereafter all the study participants entered into a
12-week treatment-free follow-up period.